Jim Cramer on Novo Nordisk: "They Are Incredibly Poorly Run"

Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer talked about. A caller asked if investors should take advantage of the recent dip and buy the stock. In response, Cramer said:

“They’re very poorly run. I don’t know this new CEO, but they are incredibly poorly run, and I’m not going to bet that they suddenly are going to change stripes… They take my breath away about how bad, how poorly they are.”

Novo Nordisk A/S (NYSE:NVO) develops and markets pharmaceutical products focused on diabetes, obesity, cardiovascular disease, and rare disorders. While discussing the stock in a July episode, Cramer said that it is not for him. He commented:

“I want you to know I don’t want Novo Nordisk… and the reason that is because if there’s going to be talk about tariffs on foreign drugs versus Eli Lilly, Novo is going to have an even less of an edge on this thing. So I say Novo, we don’t need the bottom finish. It’s not for me.”

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.